Menarini Bets $771 Million on Gan & Lee's GLP-1 in Europe

Italy's Menarini Group agreed to pay China's Gan & Lee Pharmaceuticals €62 million ($72 million) up front, in a collaboration worth up to $771 million, to register and commercialize the GLP-1 drug bofanglutide in Europe.

Menarini Group, the privately held Italian pharmaceutical company, has agreed to take a Chinese-developed GLP-1 drug into Europe, signing a collaboration with Gan & Lee Pharmaceuticals worth up to $771 million. Menarini will pay €62 million ($72 million) up front for rights tied to the registration and commercialization of bofanglutide, Gan & Lee's GLP-1 candidate, with the remainder of the headline value contingent on milestones.

The structure is the familiar shape of a cross-border licensing deal: a modest cash payment on signing, and a much larger notional total that only materializes if the drug clears regulators and sells. The up-front sum represents a small fraction of the announced $771 million ceiling, which tells you how much of the value in this agreement is still unearned.

What Gan & Lee brings and what Menarini brings

Gan & Lee is best known as an insulin manufacturer, one of the Chinese companies that built scale in a commodity-like diabetes market before pushing into newer metabolic chemistry. GLP-1 receptor agonists — the drug class that mimics a gut hormone to blunt appetite and improve blood-sugar control — are the natural adjacency for an insulin maker. The science is close to home; the commercial infrastructure in Europe is not.

That is the gap Menarini fills. The Florence-based group has a long-established European sales and distribution footprint and the regulatory experience to shepherd a file through the European Medicines Agency and then through national pricing and reimbursement negotiations, which in Europe are the harder half of the job. Gan & Lee keeps the asset's development story; Menarini takes on the grind of getting it approved and paid for in dozens of separate health systems.

The deal was reported by Fierce Biotech.

Another Chinese-origin asset crossing into Western hands

Bofanglutide is not an isolated case. Over the past few years Western pharmaceutical companies have increasingly gone shopping in China for clinical-stage molecules, licensing them for markets outside Asia rather than building or buying the underlying programs. The appeal is arithmetic: an in-licensing deal with a small up-front payment and back-loaded milestones puts far less capital at risk than an acquisition, and Chinese developers have been willing to trade Western rights for exactly that kind of paper.

Metabolic disease is where the flow has been heaviest, because the commercial prize is the largest in the industry and because the incumbents are supply-constrained rather than demand-constrained. Any company with a credible GLP-1 and no Western commercial arm has a queue of potential partners. Any company with a Western commercial arm and no GLP-1 has a strategic hole.

Menarini is in the second group. It has been broadening beyond its traditional primary-care base — its oncology unit, Stemline, gave it a specialty presence in the United States — but obesity and diabetes are territory where an established European detail force can be put to work immediately if a product clears approval.

The milestone structure is the whole negotiation

The distance between €62 million paid now and $771 million in total potential value is where the risk allocation sits. Deals of this shape typically tranche payments across development steps, regulatory filings, approvals in specific territories, and then commercial sales thresholds. Menarini pays as evidence accumulates; Gan & Lee accepts that most of the headline number depends on outcomes neither party controls.

For readers parsing these announcements, the up-front figure is the only number that is certain. Everything else is an option. That is not a criticism of the deal — it is the standard way risk is shared when a drug is not yet approved in the licensee's territory — but it does mean the $771 million should be read as a ceiling rather than a price.

Europe's obesity market is the harder commercial test

Getting a GLP-1 approved in Europe is one problem. Getting it reimbursed is another. European payers have generally been slower and more restrictive than U.S. commercial insurers on weight-management drugs, and pricing is negotiated country by country with reference-pricing systems that let one national deal drag down another. A late entrant in a class dominated by entrenched brands is likely to compete on price and supply reliability rather than on novelty.

That cuts two ways. A manufacturer with deep experience producing injectable peptides at scale — which is what an insulin company is — could be well positioned for a market where the binding constraint has been how much drug exists rather than how much doctors want to prescribe. Whether bofanglutide's clinical profile supports a differentiated position is a question the data will have to answer, and no efficacy figures were disclosed with the agreement.

What to watch from here

Three markers will show whether this deal is working. The first is a European regulatory filing and its timing, which will indicate how far along the underlying clinical package actually is. The second is whether Menarini discloses any milestone payments in future reporting, since each one confirms a step cleared. The third is whether other European mid-cap pharmaceutical companies follow with comparable in-licensing deals for Chinese metabolic assets — a pattern that would confirm this is a structural shift in where Western commercial groups source their pipelines rather than a one-off.

Market backdrop

Neither Menarini nor Gan & Lee is a U.S.-listed company, so there is no direct American equity read on the transaction. The broad market finished the session mixed: the S&P 500 tracker (NYSEARCA: SPY) closed at $770.19, down 0.39% from the prior close of $773.17, while the Nasdaq 100 tracker (NASDAQ: QQQ) closed at $718.96, up 0.18%. The Dow tracker (NYSEARCA: DIA) ended at $534.08, off 0.53%. Those are the last traded prices as of 20:00 GMT on September 4, 2026, with the market closed.

The wider signal for U.S. investors sits in the pipelines rather than the tape. Every Chinese-origin asset licensed into Western hands at a small up-front cost is a molecule that a domestic biotech did not sell at a premium, and a competitor that large-cap incumbents in the metabolic space will eventually have to price against.

Key facts

• Up-front payment: €62 million ($72 million) from Menarini to Gan & Lee
• Total deal value: Up to $771 million including milestones
• Asset and territory: Bofanglutide, a GLP-1; registration and commercialization in Europe
• Market backdrop: SPY closed at $770.19, -0.39%, as of 20:00 GMT Sept. 4, 2026

Frequently asked questions

How much is Menarini paying Gan & Lee up front?

Menarini Group agreed to pay €62 million, equivalent to about $72 million, as an up-front payment. The total announced value of the collaboration is up to $771 million, meaning the great majority of the headline figure is contingent on future development, regulatory and commercial milestones rather than guaranteed cash at signing.

What is bofanglutide?

Bofanglutide is a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals, a Chinese insulin manufacturer. GLP-1 drugs mimic a naturally occurring gut hormone that suppresses appetite and improves blood-sugar control, the same mechanism behind the leading diabetes and obesity treatments. No clinical efficacy figures were disclosed alongside the Menarini agreement.

What does Menarini get from the deal?

Menarini takes on the registration and commercialization of bofanglutide in the European market. That means preparing and filing the regulatory dossier, then negotiating pricing and reimbursement with individual national health systems, and finally selling the product through its established European commercial network.

Are Menarini or Gan & Lee listed on U.S. exchanges?

Neither company trades on a U.S. exchange. Menarini Group is a privately held Italian pharmaceutical company based in Florence. Gan & Lee Pharmaceuticals is a Chinese insulin maker. As a result there is no direct American equity vehicle through which U.S. investors can trade a reaction to this specific agreement.

Why are Western drugmakers licensing Chinese assets?

In-licensing a clinical-stage molecule with a small up-front payment and back-loaded milestones puts far less capital at risk than acquiring a company outright. Chinese developers with strong chemistry but no Western commercial infrastructure have been willing to trade rights outside Asia on those terms, and metabolic disease has seen the heaviest deal flow.

What is the biggest obstacle in the European market?

Reimbursement rather than approval. European payers have been slower and more restrictive than U.S. commercial insurers on weight-management drugs, and pricing is negotiated country by country under reference-pricing rules that let one national settlement pull down prices elsewhere. A late entrant typically competes on price and supply reliability.

Sources

• Menarini signs $771M deal to take Gan & Lee GLP-1 to European market — Fierce Biotech

Photo: freestocks.org · Pexels Licence — source